- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Circulating Tumor Cell (CTC) Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Circulating Tumor Cell (CTC) Diagnostics market size is estimated to be worth US$ 7608.8 million in 2021 and is forecast to a readjusted size of USD 19620 million by 2028 with a CAGR of 14.5% during review period. Hospitals and clinics accounting for % of the Circulating Tumor Cell (CTC) Diagnostics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CTC Enrichment segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Circulating Tumor Cell (CTC) Diagnostics include ApoCell, Inc.(US), Biocep Ltd. (Israel), Biocept, Inc.(US), Biofluidica MicrotechnologiesLLc(US), and Celltraffix Inc.(US), etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Circulating Tumor Cell (CTC) Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CTC Enrichment
CTC Detection
Market segment by Application, can be divided into
Hospitals and clinics
Pharmaceuticals and biotechnology companies
Academic research institutes
CROs
Market segment by players, this report covers
ApoCell, Inc.(US)
Biocep Ltd. (Israel)
Biocept, Inc.(US)
Biofluidica MicrotechnologiesLLc(US)
Celltraffix Inc.(US)
ClearbridgeBiomedics(Singapore)
Creatv Microtech, Inc.(US)
CynvenioBiosystems, Inc.(US)
EpicBiosciencesInc.(US)
FluxionBiosciences, Inc.(US)
Ikonisys, Inc.(US)
IVDiagnostics, Inc.(US)
JanssenDiagnosticsLLc(US)
QIAGEnHannoverGmbH (Germany)
RARECELLsSAs(Italy)
ScreenCell(France)
STEMCELlTechnologies, Inc.(Canada)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Circulating Tumor Cell (CTC) Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Circulating Tumor Cell (CTC) Diagnostics, with revenue, gross margin and global market share of Circulating Tumor Cell (CTC) Diagnostics from 2019 to 2022.
Chapter 3, the Circulating Tumor Cell (CTC) Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Circulating Tumor Cell (CTC) Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Circulating Tumor Cell (CTC) Diagnostics research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Circulating Tumor Cell (CTC) Diagnostics
1.2 Classification of Circulating Tumor Cell (CTC) Diagnostics by Type
1.2.1 Overview: Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Type in 2021
1.2.3 CTC Enrichment
1.2.4 CTC Detection
1.3 Global Circulating Tumor Cell (CTC) Diagnostics Market by Application
1.3.1 Overview: Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals and clinics
1.3.3 Pharmaceuticals and biotechnology companies
1.3.4 Academic research institutes
1.3.5 CROs
1.4 Global Circulating Tumor Cell (CTC) Diagnostics Market Size & Forecast
1.5 Global Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast by Region
1.5.1 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Region, (2017-2022)
1.5.3 North America Circulating Tumor Cell (CTC) Diagnostics Market Size and Prospect (2017-2028)
1.5.4 Europe Circulating Tumor Cell (CTC) Diagnostics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Market Size and Prospect (2017-2028)
1.5.6 South America Circulating Tumor Cell (CTC) Diagnostics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Circulating Tumor Cell (CTC) Diagnostics Market Drivers
1.6.2 Circulating Tumor Cell (CTC) Diagnostics Market Restraints
1.6.3 Circulating Tumor Cell (CTC) Diagnostics Trends Analysis
2 Company Profiles
2.1 ApoCell, Inc.(US)
2.1.1 ApoCell, Inc.(US) Details
2.1.2 ApoCell, Inc.(US) Major Business
2.1.3 ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.1.4 ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 ApoCell, Inc.(US) Recent Developments and Future Plans
2.2 Biocep Ltd. (Israel)
2.2.1 Biocep Ltd. (Israel) Details
2.2.2 Biocep Ltd. (Israel) Major Business
2.2.3 Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.2.4 Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Biocep Ltd. (Israel) Recent Developments and Future Plans
2.3 Biocept, Inc.(US)
2.3.1 Biocept, Inc.(US) Details
2.3.2 Biocept, Inc.(US) Major Business
2.3.3 Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.3.4 Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Biocept, Inc.(US) Recent Developments and Future Plans
2.4 Biofluidica MicrotechnologiesLLc(US)
2.4.1 Biofluidica MicrotechnologiesLLc(US) Details
2.4.2 Biofluidica MicrotechnologiesLLc(US) Major Business
2.4.3 Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.4.4 Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Biofluidica MicrotechnologiesLLc(US) Recent Developments and Future Plans
2.5 Celltraffix Inc.(US)
2.5.1 Celltraffix Inc.(US) Details
2.5.2 Celltraffix Inc.(US) Major Business
2.5.3 Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.5.4 Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Celltraffix Inc.(US) Recent Developments and Future Plans
2.6 ClearbridgeBiomedics(Singapore)
2.6.1 ClearbridgeBiomedics(Singapore) Details
2.6.2 ClearbridgeBiomedics(Singapore) Major Business
2.6.3 ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.6.4 ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 ClearbridgeBiomedics(Singapore) Recent Developments and Future Plans
2.7 Creatv Microtech, Inc.(US)
2.7.1 Creatv Microtech, Inc.(US) Details
2.7.2 Creatv Microtech, Inc.(US) Major Business
2.7.3 Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.7.4 Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Creatv Microtech, Inc.(US) Recent Developments and Future Plans
2.8 CynvenioBiosystems, Inc.(US)
2.8.1 CynvenioBiosystems, Inc.(US) Details
2.8.2 CynvenioBiosystems, Inc.(US) Major Business
2.8.3 CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.8.4 CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 CynvenioBiosystems, Inc.(US) Recent Developments and Future Plans
2.9 EpicBiosciencesInc.(US)
2.9.1 EpicBiosciencesInc.(US) Details
2.9.2 EpicBiosciencesInc.(US) Major Business
2.9.3 EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.9.4 EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 EpicBiosciencesInc.(US) Recent Developments and Future Plans
2.10 FluxionBiosciences, Inc.(US)
2.10.1 FluxionBiosciences, Inc.(US) Details
2.10.2 FluxionBiosciences, Inc.(US) Major Business
2.10.3 FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.10.4 FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 FluxionBiosciences, Inc.(US) Recent Developments and Future Plans
2.11 Ikonisys, Inc.(US)
2.11.1 Ikonisys, Inc.(US) Details
2.11.2 Ikonisys, Inc.(US) Major Business
2.11.3 Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.11.4 Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Ikonisys, Inc.(US) Recent Developments and Future Plans
2.12 IVDiagnostics, Inc.(US)
2.12.1 IVDiagnostics, Inc.(US) Details
2.12.2 IVDiagnostics, Inc.(US) Major Business
2.12.3 IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.12.4 IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 IVDiagnostics, Inc.(US) Recent Developments and Future Plans
2.13 JanssenDiagnosticsLLc(US)
2.13.1 JanssenDiagnosticsLLc(US) Details
2.13.2 JanssenDiagnosticsLLc(US) Major Business
2.13.3 JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.13.4 JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 JanssenDiagnosticsLLc(US) Recent Developments and Future Plans
2.14 QIAGEnHannoverGmbH (Germany)
2.14.1 QIAGEnHannoverGmbH (Germany) Details
2.14.2 QIAGEnHannoverGmbH (Germany) Major Business
2.14.3 QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.14.4 QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 QIAGEnHannoverGmbH (Germany) Recent Developments and Future Plans
2.15 RARECELLsSAs(Italy)
2.15.1 RARECELLsSAs(Italy) Details
2.15.2 RARECELLsSAs(Italy) Major Business
2.15.3 RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.15.4 RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 RARECELLsSAs(Italy) Recent Developments and Future Plans
2.16 ScreenCell(France)
2.16.1 ScreenCell(France) Details
2.16.2 ScreenCell(France) Major Business
2.16.3 ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.16.4 ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 ScreenCell(France) Recent Developments and Future Plans
2.17 STEMCELlTechnologies, Inc.(Canada)
2.17.1 STEMCELlTechnologies, Inc.(Canada) Details
2.17.2 STEMCELlTechnologies, Inc.(Canada) Major Business
2.17.3 STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
2.17.4 STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 STEMCELlTechnologies, Inc.(Canada) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Circulating Tumor Cell (CTC) Diagnostics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Circulating Tumor Cell (CTC) Diagnostics Players Market Share in 2021
3.2.2 Top 10 Circulating Tumor Cell (CTC) Diagnostics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Circulating Tumor Cell (CTC) Diagnostics Players Head Office, Products and Services Provided
3.4 Circulating Tumor Cell (CTC) Diagnostics Mergers & Acquisitions
3.5 Circulating Tumor Cell (CTC) Diagnostics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Circulating Tumor Cell (CTC) Diagnostics Revenue and Market Share by Type (2017-2022)
4.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Application (2017-2022)
5.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2028)
6.2 North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2028)
6.3 North America Circulating Tumor Cell (CTC) Diagnostics Market Size by Country
6.3.1 North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2028)
6.3.2 United States Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
6.3.3 Canada Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
6.3.4 Mexico Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2028)
7.2 Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2028)
7.3 Europe Circulating Tumor Cell (CTC) Diagnostics Market Size by Country
7.3.1 Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2028)
7.3.2 Germany Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
7.3.3 France Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
7.3.5 Russia Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
7.3.6 Italy Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2028)
8.2 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2028)
8.3 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Market Size by Region
8.3.1 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Region (2017-2028)
8.3.2 China Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8.3.3 Japan Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8.3.4 South Korea Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8.3.5 India Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
8.3.7 Australia Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2028)
9.2 South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2028)
9.3 South America Circulating Tumor Cell (CTC) Diagnostics Market Size by Country
9.3.1 South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2028)
9.3.2 Brazil Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
9.3.3 Argentina Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2028)
10.2 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2028)
10.3 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Size by Country
10.3.1 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2028)
10.3.2 Turkey Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
10.3.4 UAE Circulating Tumor Cell (CTC) Diagnostics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Circulating Tumor Cell (CTC) Diagnostics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Circulating Tumor Cell (CTC) Diagnostics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Circulating Tumor Cell (CTC) Diagnostics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Region (2023-2028)
Table 6. ApoCell, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 7. ApoCell, Inc.(US) Major Business
Table 8. ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 9. ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Biocep Ltd. (Israel) Corporate Information, Head Office, and Major Competitors
Table 11. Biocep Ltd. (Israel) Major Business
Table 12. Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 13. Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Biocept, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 15. Biocept, Inc.(US) Major Business
Table 16. Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 17. Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Biofluidica MicrotechnologiesLLc(US) Corporate Information, Head Office, and Major Competitors
Table 19. Biofluidica MicrotechnologiesLLc(US) Major Business
Table 20. Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 21. Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Celltraffix Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 23. Celltraffix Inc.(US) Major Business
Table 24. Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 25. Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. ClearbridgeBiomedics(Singapore) Corporate Information, Head Office, and Major Competitors
Table 27. ClearbridgeBiomedics(Singapore) Major Business
Table 28. ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 29. ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Creatv Microtech, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 31. Creatv Microtech, Inc.(US) Major Business
Table 32. Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 33. Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. CynvenioBiosystems, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 35. CynvenioBiosystems, Inc.(US) Major Business
Table 36. CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 37. CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. EpicBiosciencesInc.(US) Corporate Information, Head Office, and Major Competitors
Table 39. EpicBiosciencesInc.(US) Major Business
Table 40. EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 41. EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. FluxionBiosciences, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 43. FluxionBiosciences, Inc.(US) Major Business
Table 44. FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 45. FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Ikonisys, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 47. Ikonisys, Inc.(US) Major Business
Table 48. Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 49. Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. IVDiagnostics, Inc.(US) Corporate Information, Head Office, and Major Competitors
Table 51. IVDiagnostics, Inc.(US) Major Business
Table 52. IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 53. IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. JanssenDiagnosticsLLc(US) Corporate Information, Head Office, and Major Competitors
Table 55. JanssenDiagnosticsLLc(US) Major Business
Table 56. JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 57. JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. QIAGEnHannoverGmbH (Germany) Corporate Information, Head Office, and Major Competitors
Table 59. QIAGEnHannoverGmbH (Germany) Major Business
Table 60. QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 61. QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. RARECELLsSAs(Italy) Corporate Information, Head Office, and Major Competitors
Table 63. RARECELLsSAs(Italy) Major Business
Table 64. RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 65. RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. ScreenCell(France) Corporate Information, Head Office, and Major Competitors
Table 67. ScreenCell(France) Major Business
Table 68. ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 69. ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. STEMCELlTechnologies, Inc.(Canada) Corporate Information, Head Office, and Major Competitors
Table 71. STEMCELlTechnologies, Inc.(Canada) Major Business
Table 72. STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Product and Solutions
Table 73. STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Global Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 75. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 76. Breakdown of Circulating Tumor Cell (CTC) Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 77. Circulating Tumor Cell (CTC) Diagnostics Players Head Office, Products and Services Provided
Table 78. Circulating Tumor Cell (CTC) Diagnostics Mergers & Acquisitions in the Past Five Years
Table 79. Circulating Tumor Cell (CTC) Diagnostics New Entrants and Expansion Plans
Table 80. Global Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) by Type (2017-2022)
Table 81. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Share by Type (2017-2022)
Table 82. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Forecast by Type (2023-2028)
Table 83. Global Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022)
Table 84. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Forecast by Application (2023-2028)
Table 85. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 86. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 87. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 88. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 89. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 90. North America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 91. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 92. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 93. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 94. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 95. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 96. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 97. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 98. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 99. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 100. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 101. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Region (2017-2022) & (USD Million)
Table 102. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue by Region (2023-2028) & (USD Million)
Table 103. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 104. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 105. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 106. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 107. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 108. South America Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 109. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 110. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 111. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 112. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 113. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 114. Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Circulating Tumor Cell (CTC) Diagnostics Picture
Figure 2. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Type in 2021
Figure 3. CTC Enrichment
Figure 4. CTC Detection
Figure 5. Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Application in 2021
Figure 6. Hospitals and clinics Picture
Figure 7. Pharmaceuticals and biotechnology companies Picture
Figure 8. Academic research institutes Picture
Figure 9. CROs Picture
Figure 10. Global Circulating Tumor Cell (CTC) Diagnostics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global Circulating Tumor Cell (CTC) Diagnostics Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Region (2017-2028)
Figure 13. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Region in 2021
Figure 14. North America Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Circulating Tumor Cell (CTC) Diagnostics Market Drivers
Figure 20. Circulating Tumor Cell (CTC) Diagnostics Market Restraints
Figure 21. Circulating Tumor Cell (CTC) Diagnostics Market Trends
Figure 22. ApoCell, Inc.(US) Recent Developments and Future Plans
Figure 23. Biocep Ltd. (Israel) Recent Developments and Future Plans
Figure 24. Biocept, Inc.(US) Recent Developments and Future Plans
Figure 25. Biofluidica MicrotechnologiesLLc(US) Recent Developments and Future Plans
Figure 26. Celltraffix Inc.(US) Recent Developments and Future Plans
Figure 27. ClearbridgeBiomedics(Singapore) Recent Developments and Future Plans
Figure 28. Creatv Microtech, Inc.(US) Recent Developments and Future Plans
Figure 29. CynvenioBiosystems, Inc.(US) Recent Developments and Future Plans
Figure 30. EpicBiosciencesInc.(US) Recent Developments and Future Plans
Figure 31. FluxionBiosciences, Inc.(US) Recent Developments and Future Plans
Figure 32. Ikonisys, Inc.(US) Recent Developments and Future Plans
Figure 33. IVDiagnostics, Inc.(US) Recent Developments and Future Plans
Figure 34. JanssenDiagnosticsLLc(US) Recent Developments and Future Plans
Figure 35. QIAGEnHannoverGmbH (Germany) Recent Developments and Future Plans
Figure 36. RARECELLsSAs(Italy) Recent Developments and Future Plans
Figure 37. ScreenCell(France) Recent Developments and Future Plans
Figure 38. STEMCELlTechnologies, Inc.(Canada) Recent Developments and Future Plans
Figure 39. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Share by Players in 2021
Figure 40. Circulating Tumor Cell (CTC) Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 41. Global Top 3 Players Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share in 2021
Figure 42. Global Top 10 Players Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share in 2021
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 44. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Share by Type in 2021
Figure 45. Global Circulating Tumor Cell (CTC) Diagnostics Market Share Forecast by Type (2023-2028)
Figure 46. Global Circulating Tumor Cell (CTC) Diagnostics Revenue Share by Application in 2021
Figure 47. Global Circulating Tumor Cell (CTC) Diagnostics Market Share Forecast by Application (2023-2028)
Figure 48. North America Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Type (2017-2028)
Figure 49. North America Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Application (2017-2028)
Figure 50. North America Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Country (2017-2028)
Figure 51. United States Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Canada Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Mexico Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Europe Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Type (2017-2028)
Figure 55. Europe Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Application (2017-2028)
Figure 56. Europe Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Country (2017-2028)
Figure 57. Germany Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. France Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. United Kingdom Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Russia Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Italy Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Type (2017-2028)
Figure 63. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Application (2017-2028)
Figure 64. Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Region (2017-2028)
Figure 65. China Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Japan Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South Korea Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. India Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Southeast Asia Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Australia Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South America Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Type (2017-2028)
Figure 72. South America Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Application (2017-2028)
Figure 73. South America Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Country (2017-2028)
Figure 74. Brazil Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Argentina Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Sales Market Share by Application (2017-2028)
Figure 78. Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Revenue Market Share by Country (2017-2028)
Figure 79. Turkey Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Saudi Arabia Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. UAE Circulating Tumor Cell (CTC) Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
